Center for Scientific Review; Notice of Closed Meeting, 50385-50386 [2018-21646]
Download as PDF
<![CDATA[
Federal Register / Vol. 83, No. 194 / Friday, October 5, 2018 / Notices
Group; Biobehavioral Mechanisms of
Emotion, Stress and Health Study Section.
Date: October 25–26, 2018.
Time: 8:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Washington Marriott Georgetown,
1221 22nd Street NW, Washington, DC
22037.
Contact Person: Maribeth Champoux,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3182,
MSC 7759, Bethesda, MD 20892, 301–594–
3163, champoum@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Glia in Neurodysfunction.
Date: October 25, 2018.
Time: 1:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Carol Hamelink, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4192,
MSC 7850, Bethesda, MD 20892, (301) 213–
9887, hamelinc@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; HumanAnimal Interactions.
Date: October 26, 2018.
Time: 12:00 p.m. to 12:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: Washington Marriott Georgetown,
1221 22nd Street NW, Washington, DC
22037.
Contact Person: Maribeth Champoux,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3170,
MSC 7848, Bethesda, MD 20892, 301–594–
3163, champoum@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: September 28, 2018.
Sylvia L. Neal,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2018–21648 Filed 10–4–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
daltland on DSKBBV9HB2PROD with NOTICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
VerDate Sep<11>2014
17:11 Oct 04, 2018
Jkt 247001
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; P01 Program Project
Grant.
Date: October 23, 2018.
Time: 1:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892 (Telephone
Conference Call).
Contact Person: Peter J. Kozel, Ph.D.,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 7009, 6707 Democracy Boulevard,
Bethesda, MD 20892–5452, 301–594–4721,
Kozelp@niddk.nih.gov.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; NIDDK Fatty Liver
and HIV Ancillary Studies.
Date: November 2, 2018.
Time: 1:30 p.m. to 2:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892 (Telephone
Conference Call).
Contact Person: Elena Sanovich, Ph.D.,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 7351, 6707 Democracy Boulevard,
Bethesda, MD 20892–2542, 301–594–8886,
sanoviche@mail.nih.gov.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; NIDDK
Undergraduate Summer Research
Applications (R25).
Date: November 6, 2018.
Time: 1:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892 (Telephone
Conference Call).
Contact Person: Jason D. Hoffert, Ph.D.,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 7343, 6707 Democracy Boulevard,
Bethesda, MD 20817, 301–496–9010,
hoffertj@niddk.nih.gov.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; NIDDK Fatty Liver
Ancillary Studies.
Date: November 7, 2018.
Time: 1:00 p.m. to 2:00 p.m.
PO 00000
Frm 00055
Fmt 4703
Sfmt 4703
50385
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892.
Contact Person: Elena Sanovich, Ph.D.,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 7351, 6707 Democracy Boulevard,
Bethesda, MD 20892–2542, 301–594–8886,
sanoviche@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
Dated: October 1, 2018.
David D. Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2018–21647 Filed 10–4–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Clinical
Neuroimmunology and Brain Tumors.
Date: October 11, 2018.
Time: 10:30 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Doubletree Hotel Bethesda
(Formerly Holiday Inn Select), 8120
Wisconsin Avenue, Bethesda, MD 20814.
Contact Person: Samuel C. Edwards, Ph.D.,
Chief, Brain Disorders and Clinical
Neuroscience, Center for Scientific Review,
National Institutes of Health, 6701 Rockledge
Drive, Room 5210, MSC 7846, Bethesda, MD
20892, (301) 435–1246, edwardss@
csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
E:\FR\FM\05OCN1.SGM
05OCN1
50386
Federal Register / Vol. 83, No. 194 / Friday, October 5, 2018 / Notices
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: September 28, 2018.
Sylvia L. Neal,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2018–21646 Filed 10–4–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Agency Information Collection
Activities Under Emergency Review by
the Office of Management and Budget
The Substance Abuse and Mental
Health Services Administration
(SAMHSA) has submitted the following
request (see below) for emergency OMB
review under the Paperwork Reduction
Act (44 U.S.C. Chapter 35). OMB
approval has been requested by October
25, 2018. A copy of the information
collection plans may be obtained by
calling the SAMHSA Reports Clearance
Officer on (240) 276–1243.
Title: 2019 National Survey on Drug
Use and Health.
OMB Number: 0930–0110.
Frequency: Annual.
Affected Public: Individuals or
Households.
The National Survey on Drug Use and
Health (NSDUH) is a survey of the U.S.
civilian, non-institutionalized
population aged 12 years old or older.
The data are used to determine the
prevalence of use of tobacco products,
alcohol, illicit substances, and illicit use
of prescription drugs. The results are
used by SAMHSA, the Office of
National Drug Control Policy (ONDCP),
federal government agencies, and other
organizations and researchers to
establish policy, direct program
activities, and better allocate resources.
While NSDUH must be updated
periodically to reflect changing
substance use and mental health issues
and to continue producing current data,
for the 2019 NSDUH only the following
minor changes are planned: (1) Adding
a brief series of questions on
medication-assistance treatment (MAT)
for opioids and alcohol; (2) two
questions about the use of kratom (a
tropical tree, native to Southeast Asia,
with leaves that have psychotropic
effects and is generally regarded as an
opioid given its known properties); and
(3) included other minor wording
changes to improve the flow of the
interview, increase respondent
comprehension or to be consistent with
text in other questions.
The series of MAT questions seeks to
identify medications prescribed by
health professionals to help reduce or
stop the use of opioids or alcohol.
Including these questions in NSDUH
will allow SAMHSA to provide the first
known national-level estimates on the
use of MAT for opioid use disorder or
alcohol use disorder. The two questions
on kratom will provide the first
national, systematic epidemiological or
survey data on its use in this country
and establish a baseline for the use of
kratom—an easily accessible,
unregulated, opioid-like drug. Not
currently illegal in the United States,
kratom is easy to order on the internet,
typically ingested as a leaf, pill or
capsule and contains chemical
compounds which interact with opioid
receptors in the brain. Some users of
kratom products reported becoming
addicted to the drug.
As with all NSDUH/NHSDA (Prior to
2002, the NSDUH was referred to as the
National Household Survey on Drug
Abuse) surveys conducted since 1999,
the sample size of the survey for 2019
will be sufficient to permit prevalence
estimates for each of the fifty states and
the District of Columbia. The total
annual burden estimate is shown below
in Table 1.
TABLE 1—ANNUALIZED ESTIMATED BURDEN FOR 2019 NSDUH
Number of
respondents
daltland on DSKBBV9HB2PROD with NOTICES
Instrument
Responses
per respondent
Total number
of responses
Hours per
response
Total
burden hours
Household Screening ...........................................................
Interview ...............................................................................
Screening Verification ..........................................................
Interview Verification ............................................................
137,231
67,507
4,116
10,126
1
1
1
1
137,231
67,507
4,116
10,126
0.083
1.000
0.067
0.067
11,390
67,507
276
678
Total ..............................................................................
137,231
........................
218,980
........................
79,851
Emergency approval is being
requested because SAMHSA has
determined that the kratom questions
will provide the first national,
systematic epidemiological or survey
data on its use in this country and
establish a baseline for the use of
kratom—an easily accessible,
unregulated, opioid-like drug. Some
users of kratom products reported
becoming addicted to the drug. Because
of these additional questions, this
Federal Register notice is a revision
from the one that was published on May
31, 2018.
Written comments and
recommendations concerning the
proposed information collection should
be sent by October 24, 2018 Elyse
VerDate Sep<11>2014
17:11 Oct 04, 2018
Jkt 247001
Greenwald, SAMHSA’s Desk Officer at
the Office of Information and Regulatory
Affairs, Office of Management and
Budget (OMB). To ensure timely receipt
of comments, and to avoid potential
delays in OMB’s receipt and processing
of mail sent through the U.S. Postal
Service, commenters are encouraged to
submit their comments to OMB via
email to: OIRA_Submission@
omb.eop.gov. Although commenters are
encouraged to send their comments via
email, commenters may also fax their
comments to: 202–395–7285.
Commenters may also mail them to:
Office of Management and Budget,
Office of Information and Regulatory
PO 00000
Frm 00056
Fmt 4703
Sfmt 9990
Affairs, New Executive Office Building,
Room 10102, Washington, DC 20503.
Summer King,
Statistician.
[FR Doc. 2018–21716 Filed 10–4–18; 8:45 am]
BILLING CODE 4162–20–P
E:\FR\FM\05OCN1.SGM
05OCN1
]]>Agencies
[Federal Register Volume 83, Number 194 (Friday, October 5, 2018)]
[Notices]
[Pages 50385-50386]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-21646]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Clinical Neuroimmunology and Brain Tumors.
Date: October 11, 2018.
Time: 10:30 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Doubletree Hotel Bethesda (Formerly Holiday Inn Select),
8120 Wisconsin Avenue, Bethesda, MD 20814.
Contact Person: Samuel C. Edwards, Ph.D., Chief, Brain Disorders
and Clinical Neuroscience, Center for Scientific Review, National
Institutes of Health, 6701 Rockledge Drive, Room 5210, MSC 7846,
Bethesda, MD 20892, (301) 435-1246, [email protected].
This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review and
funding cycle.
[[Page 50386]]
(Catalogue of Federal Domestic Assistance Program Nos. 93.306,
Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893,
National Institutes of Health, HHS)
Dated: September 28, 2018.
Sylvia L. Neal,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2018-21646 Filed 10-4-18; 8:45 am]
BILLING CODE 4140-01-P
